We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends approval of GSK's IV Benlysta in children with lupus aged five years and above
Alexion Pharmaceuticals announced the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to extend the current marketing authorization of SOLIRIS® (eculizumab) to ...